Terran Biosciences Announces Development of TerXT, a Combination of Xanomeline and Trospium Prodrugs for the Treatment of Schizophrenia, and Intends to Pursue Accelerated 505(b)(2) Approval Pathway
Terran Biosciences Receives FDA Clearance for NM-101, the industry’s first software for the analysis of neuromelanin-sensitive MRI
Terran Biosciences Receives Notice of Allowance for Four US Patents
The Lexington, MA biotech announced topline data Monday morning that indicated the primary endpoint, plus all “key secondary endpoints,” were met. The topline data came from THRIVE-AA1, a Phase III trial with more than 700 participants enrolled and one of Concert’s two Phase III trials investigating drug candidate CTP-543.
A fledgling New York biotech has managed to catch the eye of Sanofi, signing a new collaboration with the pharma giant to acquire two of its programs — but giving away few other details.